[go: up one dir, main page]

AU2001289707A1 - Method for the detection of apoptosis by determining apoptosis-specific markers released into an extracellular medium through cellular release mechanisms - Google Patents

Method for the detection of apoptosis by determining apoptosis-specific markers released into an extracellular medium through cellular release mechanisms

Info

Publication number
AU2001289707A1
AU2001289707A1 AU2001289707A AU8970701A AU2001289707A1 AU 2001289707 A1 AU2001289707 A1 AU 2001289707A1 AU 2001289707 A AU2001289707 A AU 2001289707A AU 8970701 A AU8970701 A AU 8970701A AU 2001289707 A1 AU2001289707 A1 AU 2001289707A1
Authority
AU
Australia
Prior art keywords
apoptosis
specific markers
extracellular
release mechanisms
detection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001289707A
Inventor
Wolfgang E. Berdel
Marek Los
Andrea Renz
Klaus Schulze-Osthoff
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Evotec OAI AG
Original Assignee
Evotec OAI AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evotec OAI AG filed Critical Evotec OAI AG
Publication of AU2001289707A1 publication Critical patent/AU2001289707A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0006—Oxidoreductases (1.) acting on CH-OH groups as donors (1.1)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/795—Porphyrin- or corrin-ring-containing peptides
    • C07K14/80—Cytochromes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/795—Porphyrin- or corrin-ring-containing peptides
    • G01N2333/80—Cytochromes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/904—Oxidoreductases (1.) acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A method for the detection of apoptosis by determining presence, amount, or activity of apoptosis-specific markers released from at least one cell undergoing apoptosis into an extracellular medium through cellular release mechanisms is disclosed. The extracellular medium includes body fluids, in particular urine, inflammatory fluid, serum, liquor, or cell culture medium, wherein samples are preferably taken from humans or animals. The method can be used for the diagnosis and/or for therapy control of diseases and/or processes associated with increased apoptosis. It can also be used for therapy control of diseases associated with decreased apoptosis. Additionally, a method is disclosed for the identification of apoptosis-modulating substances, characterized in that apoptosis-specific markers released from a cell culture sample into an extracellular cell culture medium through cellular release mechanisms are determined. The invention also concerns the use of an apoptosis detection kit for determining extracellular apoptosis-specific markers. It further relates to the use of cytochrome c and/or peptides derived thereof as a medicament, pharmaceutical compositions comprising cytochrome c and/or peptides derived thereof, and optionally a pharmaceutically acceptable carrier, and the use of cytochrome c and/or peptides derived thereof, for the preparation of a medicament for the treatment of diseases with inflammatory manifestation.
AU2001289707A 2000-07-21 2001-07-20 Method for the detection of apoptosis by determining apoptosis-specific markers released into an extracellular medium through cellular release mechanisms Abandoned AU2001289707A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP00115722 2000-07-21
EP00115722 2000-07-21
EP00119818 2000-09-12
EP00119818 2000-09-12
PCT/EP2001/008389 WO2002008752A1 (en) 2000-07-21 2001-07-20 Method for the detection of apoptosis by determining apoptosis-specific markers released into an extracellular medium through cellular release mechanisms

Publications (1)

Publication Number Publication Date
AU2001289707A1 true AU2001289707A1 (en) 2002-02-05

Family

ID=26071195

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001289707A Abandoned AU2001289707A1 (en) 2000-07-21 2001-07-20 Method for the detection of apoptosis by determining apoptosis-specific markers released into an extracellular medium through cellular release mechanisms

Country Status (6)

Country Link
US (2) US20040043435A1 (en)
EP (1) EP1301786B1 (en)
AT (1) ATE311595T1 (en)
AU (1) AU2001289707A1 (en)
DE (1) DE60115453T2 (en)
WO (1) WO2002008752A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2288877T3 (en) * 1999-11-08 2008-02-01 EISAI R&D MANAGEMENT CO., LTD. METHOD AND REAGENT TO DETECT CELL DEATH.
GB0108143D0 (en) * 2001-03-31 2001-05-23 Univ Dundee High-throughput screen
GB0329353D0 (en) * 2003-12-19 2004-01-21 Amersham Biosciences Uk Ltd Cytochrome C protein and assay
FR2915393B1 (en) 2007-04-27 2012-12-14 Vincience PHARMACEUTICAL AND / OR COSMETIC COMPOSITION CONTAINING CYTOCHROME C ACTIVE ACTIVATOR
FR2915394B1 (en) * 2007-04-27 2012-12-14 Vincience PHARMACEUTICAL AND / OR COSMETIC COMPOSITION CONTAINING PEPTIDES

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3642978A (en) * 1969-03-05 1972-02-15 Mochida Pharm Co Ltd Process for producing stable cytochrome c preparation
JPS60100517A (en) * 1983-11-08 1985-06-04 Eisai Co Ltd Radiation remedy for ulcer and method
JPS6339813A (en) * 1986-08-05 1988-02-20 Eisai Co Ltd Remedy for wound
US5972622A (en) * 1996-02-08 1999-10-26 Desjardins; Louise Method of detecting apoptosis using an anti-human GP46 monoclonal anti-body
US6048703A (en) * 1996-11-15 2000-04-11 Cephalon, Inc. Methods for detecting cell apoptosis
US5928860A (en) * 1997-02-25 1999-07-27 Kloth; Sabine Process for determining the tolerance, or toxicity of gaseous, liquid and/or viscous substances for the human or animal organism
AU6162999A (en) * 1998-09-24 2000-04-10 Promega Corporation Apoptosis marker antibodies and methods of use
US6140067A (en) * 1999-04-30 2000-10-31 Mitokor Indicators of altered mitochondrial function in predictive methods for determining risk of type 2 diabetes mellitus

Also Published As

Publication number Publication date
US20070243577A1 (en) 2007-10-18
WO2002008752A1 (en) 2002-01-31
EP1301786B1 (en) 2005-11-30
DE60115453D1 (en) 2006-01-05
DE60115453T2 (en) 2006-08-24
EP1301786A1 (en) 2003-04-16
ATE311595T1 (en) 2005-12-15
US20040043435A1 (en) 2004-03-04

Similar Documents

Publication Publication Date Title
TW408182B (en) Assay for proline iminopeptidase and other hydrolytic activities
WO2004076639B1 (en) Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus
WO2001075171A3 (en) Methods, compositions and kits for the detection and monitoring of breast cancer
WO2000060077A3 (en) Compounds for therapy and diagnosis of lung cancer and methods for their use
Gautier et al. Evaluation of novel biomarkers of nephrotoxicity in Cynomolgus monkeys treated with gentamicin
NZ601022A (en) Diagnosis and treatment of cancer using anti-ereg antibody
WO2000060076A3 (en) Compositions for the treatment and diagnosis of breast cancer and methods for their use
WO2001040269A3 (en) Compositions and methods for therapy and diagnosis of breast cancer
WO2001000828A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
WO2001096388A3 (en) Compositions and methods for the therapy and diagnosis of colon cancer
WO2006073682A3 (en) Diagnostic test
WO2002059604A3 (en) Diagnosis and treatment of multiple sclerosis
WO2001079286A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
WO2001073027A3 (en) Compositions and methods for therapy and diagnosis of colon cancer
WO2003092601A3 (en) A method for detecting lysosomal storage diseases
MX2009001070A (en) Use of melanoma inhibitory activity (mia) protein as an early indicator for therapeutic response in melanoma.
AU2001289707A1 (en) Method for the detection of apoptosis by determining apoptosis-specific markers released into an extracellular medium through cellular release mechanisms
WO2007071829A3 (en) Methods and means related to diseases
WO2000078960A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
KR20190080149A (en) Biomarker composition for diagnosing susceptibility to hepatotoxicity and diagnosing method thereof
WO2002059611A3 (en) Diagnosis and treatment of cancer using mammalian pellino polypeptides and polynucleotides
Girard et al. Subcutaneous phaeohyphomycosis due to Pyrenochaeta romeroi in a patient with leprosy
WO2001062785A3 (en) Protein and gene and their use for diagnosis and treatment of schizophrenia
WO2003014394A1 (en) Method of evaluating biocompatibility
WO2001070976A3 (en) Compositions and methods for the therapy and diagnosis of ovarian and endometrial cancer